Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 3 April 2024, 15:24 HKT/SGT
Share:
    

Source: Eisai
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the “Territory”) for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited. Following the signature of this agreement, a transition period had opened during which the required implementation steps will be carried out in order for CNX to become able to operate directly the business, including the regulatory steps for the transfer of the relevant marketing authorizations and exploitant status. Under the terms of the agreement, Eisai S.A.S. will receive 56.5 million euro as a lump-sum contract payment upon completing the transaction. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.

Eisai S.A.S. acquired the rights to both treatments in the Territory in July 2002 and has been marketing them since. With the conclusion of this agreement, Eisai believes that the value of both treatments in the Territory will be maximized based on CNX’s ongoing commitment serving patients in to the fields of psychiatry and neurology.

Driven by our hhc concept, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas: Neurology, Oncology and Global Health. As an hhc eco company, Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities by creating solutions through building an ecosystem in collaboration with other industries.

About CNX Therapeutics Limited

CNX Therapeutics  ("CNX") is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercializes and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 40 countries worldwide, both directly and through strategic partnerships.

CNX is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and niche injectable products, which is committed to the highest standards of ethics and sustainability.

CNX has a pioneering approach to Environment, Social and Governance (ESG), which forms a key part of its mission.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Oct 2, 2024 10:28 HKT/SGT
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Sept 24, 2024 15:06 HKT/SGT
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Sept 24, 2024 14:01 HKT/SGT
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Sept 17, 2024 09:08 HKT/SGT
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sept 5, 2024 15:59 HKT/SGT
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sept 2, 2024 14:12 HKT/SGT
Eisai Announces Status Relating to Acquisition of Own Shares
Aug 22, 2024 18:54 HKT/SGT
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Aug 14, 2024 08:59 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Aug 6, 2024 12:15 HKT/SGT
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
July 31, 2024 12:59 HKT/SGT
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: